BioPlus Acquisition Corp.
Status: Liquidated
U=S+W/2
W=S@11.50
| IPO Proceeds, $M | $230.00M |
|---|---|
| IPO Date | Dec 3, 2021 |
| CEO | Ross Haghighat |
| Left Lead | Cantor Fitzgerald |
| IPO Cash in Trust | 102.0% |
| SPAC Tenor | 18 + 6 |
| IPO Sector |
Healthcare
Life sciences (globally excluding China, Hong Kong and Macau) |
| IPO Geography | Global |
| Target Company | N/A |
| Deal Announced | N/A |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Jun 2, 2023 |
| Closing Date | Oct 9, 2023 |
BIOS
BIOSU
BIOSW
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
| Price | |
|---|---|
| Volume, today | |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on BioPlus Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 18 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Jonathan Rigby | 53 | Chairman and Chief Business Officer |
| Ross Haghighat | 57 | Chief Executive Officer, Chief Financial Officer and Director |
| Ronald Eastman | 69 | Vice Chairman |
| Shawn Cross | 53 | Director |
| Louis G. Lange, M.D., Ph.D. | 72 | Director |
| Stephen Sherwin, M.D. | 72 | Director |
| Glen Giovannetti | 58 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Cantor Fitzgerald | BR | 20,000,000 | units |
| 20,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee | 4.00 | % |
Sign in to view more advisor data.
Filings
Sign in to view 18 filings.